Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int J Cancer, vol.15, issue.8, pp.1941-53, 2019. ,
,
, Rev Stomatol Chir Maxillofac. juin, vol.112, issue.3, pp.164-71, 2011.
Race and gender influences on the survival of patients with mouth cancer, J Clin Epidemiol. janv, vol.46, issue.1, pp.37-46, 1993. ,
Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report, Head Neck. févr, vol.24, issue.2, pp.165-80, 2002. ,
Comparison of oral squamous cell carcinoma in younger and older patients in India, Eur J Cancer, B, Oral Oncol, vol.28, issue.2, pp.113-133, 1992. ,
The prognostic relevance of various factors at the time of the first admission of the patient. Retrospective DOSAK study on carcinoma of the oral cavity, J Maxillofac Surg. févr, vol.11, issue.1, pp.3-12, 1983. ,
Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer, Arch Otolaryngol Head Neck Surg. févr, vol.129, issue.2, pp.219-247, 2003. ,
Survival, metastasis and recurrence of oral cancer in relation to pathological features, Ann R Coll Surg Engl. sept, vol.77, issue.5, pp.325-356, 1995. ,
Squamous cell carcinoma of the tongue: a comparison of the anterior two thirds of the tongue with its base, Am J Surg, vol.146, issue.4, pp.456-61, 1983. ,
Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection, Oral Oncol. mai, vol.35, issue.3, pp.257-65, 1999. ,
Hayes Martin lecture. Vicissitudes of head and neck cancer, Am J Surg, vol.148, issue.4, pp.428-460, 1984. ,
Prognosis in mouth cancer: tumour factors, Eur J Cancer, B, Oral Oncol. janv, vol.30, issue.1, pp.8-15, 1994. ,
Relevant changes in the AJCC 8th edition staging manual for oral cavity cancer and future implications, Chin Clin Oncol. 20 mars, 2019. ,
Prognostic implications of the 8th edition American Joint Committee on Cancer (AJCC) staging system in oral cavity squamous cell carcinoma, Oral Oncol. oct, vol.85, pp.82-88, 2018. ,
Predictive value of tumor thickness in squamous carcinoma confined to the tongue and floor of the mouth, Am J Surg, vol.152, issue.4, pp.345-50, 1986. ,
Evaluation of some prognostic factors in small squamous cell carcinoma of the mobile tongue: a multicenter study in Sweden. Head Neck, vol.11, pp.387-92, 1989. ,
Significance of tumor thickness in soft palate carcinoma, Laryngoscope. avr, vol.103, issue.4, pp.389-93, 1993. ,
Prognostic factors of clinically stage I and II oral tongue carcinoma-A comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score, and pathologic features, Head Neck. juin, vol.24, issue.6, pp.513-533, 2002. ,
Primary tumor staging for oral cancer and a proposed modification incorporating depth of invasion: an international multicenter retrospective study, JAMA Otolaryngol Head Neck Surg. déc, vol.39, issue.4, pp.1138-1186, 2003. ,
Clinical outcomes for T1-2N0-1 oral tongue cancer patients underwent surgery with and without postoperative radiotherapy, Radiat Oncol. 27 mai, vol.5, p.43, 2010. ,
Microscopic cut-through of cancer in the surgical treatment of squamous carcinoma of the tongue. Prognostic and therapeutic implications, Am J Surg, vol.152, issue.4, pp.354-60, 1986. ,
The prognostic implications of the surgical margin in oral squamous cell carcinoma, Int J Oral Maxillofac Surg. févr, vol.32, issue.1, pp.30-34, 2003. ,
Significance of positive margins in oral cavity squamous carcinoma, Am J Surg. oct, vol.160, issue.4, pp.410-414, 1990. ,
Prognostic factors of neck node metastasis, Clin Otolaryngol Allied Sci. juin, vol.7, issue.3, pp.185-92, 1982. ,
Correlation between prognosis and degree of lymph node involvement in carcinoma of the oral cavity, Am J Surg, vol.134, issue.4, pp.450-454, 1977. ,
Neck dissection in oral cancer--clinical review and analysis of prognostic factors, Int J Oral Maxillofac Surg. déc, vol.31, issue.6, pp.608-622, 2002. ,
Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas, Am J Surg. mars, vol.185, issue.3, pp.278-84, 2003. ,
Prognostic indicators for survival in head and neck squamous cell carcinomas: analysis of a series of 621 cases, Head Neck. sept, vol.27, issue.9, pp.801-809, 2005. ,
Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread, Oral Oncol. févr, vol.39, issue.2, pp.130-137, 2003. ,
Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue, Cancer. 15 déc, vol.92, issue.12, pp.1192-1199, 2001. ,
Inclusion of extracapsular spread in the pTNM classification system: a proposal for patients with head and neck carcinoma, JAMA Otolaryngol Head Neck Surg. mai, vol.139, issue.5, pp.483-491, 2013. ,
Prognostic significance of histologic grade in epidermoid carcinoma of the mouth and pharynx, Am J Surg, vol.124, issue.4, pp.489-92, 1972. ,
The prediction of lymph node metastases from oral squamous carcinoma, Cancer. avr, vol.37, issue.4, pp.1901-1908, 1976. ,
Microvascular invasion and survival in cancer of the oral cavity and oropharynx, Arch Otolaryngol Head Neck Surg, vol.115, issue.11, pp.1304-1313, 1989. ,
Prognostic significance of perineural invasion in oral and oropharyngeal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, avr, vol.97, issue.4, pp.423-454, 2004. ,
Perineural invasion in squamous cell carcinoma of the head and neck, Arch Otolaryngol Head Neck Surg. juin, vol.124, issue.6, pp.637-677, 1998. ,
The influence of the pattern of mandibular invasion on recurrence and survival in oral squamous cell carcinoma. Head Neck, vol.26, pp.861-870, 2004. ,
Prognostic significance of skin involvement from mucosal tumors of the head and neck. Arch Otolaryngol Head Neck Surg, vol.121, pp.1246-1254, 1995. ,
Prognostic value of epidermal growth factor receptor, Bull Cancer, vol.90, pp.192-196, 2003. ,
EGFR and cancer prognosis, Eur J Cancer. sept, vol.37, issue.4, pp.9-15, 2001. ,
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med. 9 févr, vol.354, issue.6, pp.567-78, 2006. ,
,
, Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study, J Clin Oncol. 1 déc, vol.23, issue.34, pp.8646-54, 2005.
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck, J Clin Oncol. 20 août, vol.23, issue.24, pp.5568-77, 2005. ,
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinumbased therapy, J Clin Oncol. 1 juin, vol.25, issue.16, pp.2171-2178, 2007. ,
Psyrri A, DiMaio D. Human papillomavirus in cervical and head-and-neck cancer, Arch Otolaryngol Head Neck Surg. mai, vol.123, issue.5, pp.24-31, 1997. ,
Human papillomavirus and survival of patients with oropharyngeal cancer, N Engl J Med. 1 juill, vol.363, issue.1, pp.24-35, 2010. ,
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial, J Natl Cancer Inst. 20 févr, vol.100, issue.4, pp.261-270, 2008. ,
Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas, Int J Cancer. 15 juin, vol.122, issue.12, pp.2656-64, 2008. ,
p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma, Arch Otolaryngol Head Neck Surg. juill, vol.122, issue.7, pp.1580-1586, 1996. ,
Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastases, Head Neck. janv, vol.26, issue.1, pp.22-30, 2004. ,
p53 and Ki-67 as markers of radioresistance in head and neck carcinoma, Cancer. 1 févr, vol.94, issue.3, pp.713-735, 2002. ,
p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck, J Clin Oncol. janv, vol.18, issue.2, pp.385-94, 2000. ,
p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series, J Clin Oncol. avr, vol.18, issue.7, pp.1465-73, 2000. ,
Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck, Arch Otolaryngol Head Neck Surg. mai, vol.123, issue.5, pp.497-502, 1997. ,
Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis, Arch Otolaryngol Head Neck Surg. juill, vol.121, issue.7, pp.790-794, 1995. ,
Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual, CA Cancer J Clin, vol.67, issue.2, pp.122-159, 2017. ,
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck, N Engl J Med. 12 avr, vol.344, issue.15, pp.1125-1156, 2001. ,
Do high-risk human papillomaviruses cause oral cavity squamous cell carcinoma?, Oral Oncol. mars, vol.51, issue.3, pp.229-265, 2015. ,
Dietary indicators of oral and pharyngeal cancer, Int J Epidemiol. mars, vol.20, issue.1, pp.39-44, 1991. ,
Increased salivary acetaldehyde levels in heavy drinkers and smokers: a microbiological approach to oral cavity cancer, Carcinogenesis. avr, vol.21, issue.4, pp.663-671, 2000. ,
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients, Radiother Oncol. juill, vol.92, issue.1, pp.4-14, 2009. ,
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer, N Engl J Med. 6 mai, vol.350, issue.19, pp.1945-52, 2004. ,
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck, N Engl J Med. 6 mai, vol.350, issue.19, pp.1937-1981, 2004. ,
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer, J Clin Oncol. 1 sept, vol.32, issue.25, pp.2735-2778, 2014. ,
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial, Lancet Oncol. mars, vol.14, issue.3, pp.257-64, 2013. ,
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer, Ann Oncol. janv, vol.25, issue.1, pp.216-241, 2014. ,
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial, Ann Oncol. 1 sept, vol.28, issue.9, pp.2206-2218, 2017. ,
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study, Ann Oncol. sept, vol.26, issue.9, pp.1941-1948, 2015. ,
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, N Engl J Med, vol.10, pp.1856-67, 2016. ,
Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, vol.363, issue.8, pp.711-734, 2010. ,
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015. ,
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.373, pp.1803-1816, 2015. ,
,
, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet. 7 mai, vol.387, pp.1909-1929, 2016.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N Engl J Med. 05, vol.377, issue.14, pp.1345-56, 2017. ,
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N Engl J Med. 5 avr, vol.378, issue.14, pp.1277-90, 2018. ,
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma, JAMA. 19 avr, vol.315, issue.15, pp.1600-1609, 2016. ,
Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med. 22 janv, vol.372, issue.4, pp.320-350, 2015. ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015. ,
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study, Lancet, vol.12, pp.156-67, 2019. ,
A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), JCO. 20 mai, vol.37, pp.6012-6012, 2019. ,
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, Lancet, vol.24, pp.748-57, 2018. ,
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N Engl J Med, vol.22, issue.25, pp.2415-2441, 2017. ,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.10, issue.19, pp.1823-1856, 2016. ,
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med. juin, vol.23, issue.6, pp.703-716, 2017. ,
Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature. 11 juill, vol.499, issue.7457, pp.214-222, 2013. ,
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, vol.19, issue.1, p.34, 2017. ,
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med. 25 juin, vol.372, issue.26, pp.2509-2529, 2015. ,
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov. janv, vol.5, issue.1, pp.43-51, 2015. ,
Tumor Mutational Burden and Response Rate to PD-1 Inhibition ,
, N Engl J Med, vol.21, issue.25, pp.2500-2501, 2017.
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers, Mol Cancer Ther, vol.16, issue.11, pp.2598-608, 2017. ,
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, vol.350, issue.6257, pp.207-218, 2015. ,
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science. 3 avr, vol.348, issue.6230, pp.124-132, 2015. ,
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell. 24 mars, vol.165, issue.1, pp.35-44, 2016. ,
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N Engl J Med. 31 mai, vol.378, issue.22, pp.2093-104, 2018. ,
Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis, Int J Cancer, vol.15, issue.4, pp.848-58, 2019. ,
Clinical and histological prognostic factors in locally advanced oral cavity cancers treated with primary surgery, Eur Ann Otorhinolaryngol Head Neck Dis. déc, vol.129, issue.6, pp.291-297, 2012. ,
Evaluation of size in prognosis of oral cancer, Cancer. 1 juill, vol.58, issue.1, pp.158-62, 1986. ,
Survival Rates According to Tumour Location in Patients With Surgically Treated Oral and Oropharyngeal Squamous Cell Carcinoma, Anticancer Res. mai, vol.39, issue.5, pp.2527-2560, 2019. ,
TP53 mutation and human papilloma virus status of oral squamous cell carcinomas in young adult patients, Oral Dis. sept, vol.20, issue.6, pp.602-610, 2014. ,
Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience, J Oral Maxillofac Surg. sept, vol.66, issue.9, pp.1875-80, 2008. ,
Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA, Oral Oncol. juin, vol.49, issue.6, pp.525-558, 2013. ,
Human papillomavirus (HPV) status of nontobacco related squamous cell carcinomas of the lateral tongue, Oral Oncol. avr, vol.50, issue.4, pp.306-316, 2014. ,
The status of the resection margin as a prognostic factor in the treatment of head and neck carcinoma, J Craniomaxillofac Surg. oct, vol.19, issue.7, pp.314-322, 1991. ,
Squamous cell carcinoma with positive margins. Surgery and postoperative irradiation, Arch Otolaryngol Head Neck Surg. août, vol.112, issue.8, pp.863-869, 1986. ,
, Clinicopathological parameters and outcome of 245 patients operated for oral squamous cell carcinoma, J Craniomaxillofac Surg. sept, vol.34, issue.6, pp.344-50, 2006.
Squamous cell carcinoma of the oral tongue: an analysis of prognostic factors, Br J Oral Maxillofac Surg. juin, vol.38, issue.3, pp.193-202, 2000. ,
Prognostic factors in tongue cancer -relative importance of demographic, clinical and histopathological factors, Br J Cancer. sept, vol.83, issue.5, pp.614-623, 2000. ,
Prognostic factors in patients with buccal squamous cell carcinoma: 10-year experience, J Oral Maxillofac Surg. févr, vol.69, issue.2, pp.396-404, 2011. ,
The impact of lymphovascular invasion on survival in oral carcinoma, Oral Oncol. janv, vol.45, issue.1, pp.10-15, 2009. ,
Clinicobiological progression and prognosis of oral squamous cell carcinoma in relation to the tumor invasive front: impact on prognosis, Acta Otolaryngol. avr, vol.134, issue.4, pp.416-440, 2014. ,
Invasion of the microcirculation in head and neck cancer, Ann Otol Rhinol Laryngol. déc, vol.93, issue.6, pp.646-653, 1984. ,
Lymph node prognostic factors in head and neck squamous cell carcinomas, Am J Surg, vol.168, issue.5, pp.494-502, 1994. ,
Radical neck dissections for squamous carcinomas: pathological findings and their clinical implications with particular reference to transcapsular spread, Int J Radiat Oncol Biol Phys. juin, vol.13, issue.6, pp.825-857, 1987. ,
Extracapsular spread of squamous cell carcinoma in neck lymph nodes: prognostic factor of laryngeal cancer, Laryngoscope. mai, vol.101, issue.5, pp.502-508, 1991. ,
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic, Ann Oncol. 1 janv, vol.30, issue.1, pp.44-56, 2019. ,
Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer, Dis Markers, p.3837687, 2019. ,
Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers, Eur J Cancer. févr, vol.35, issue.2, pp.197-201, 1999. ,
Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences, Am J Pathol. juill, vol.145, issue.1, pp.148-56, 1994. ,
Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator, Mod Pathol. mai, vol.3, issue.3, pp.332-337, 1990. ,
Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group, Eur J Cancer. juill, vol.116, pp.67-76, 2019. ,
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028, J Clin Oncol. 1 févr, vol.37, issue.4, pp.318-345, 2019. ,
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy, Nat Rev Cancer. févr, vol.14, issue.2, pp.135-181, 2014. ,
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells, Science. 15 mai, vol.348, issue.6236, pp.803-811, 2015. ,
Signatures of mutational processes in human cancer, Nature. 22 août, vol.500, issue.7463, pp.415-436, 2013. ,
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science. 25 mars, vol.351, issue.6280, pp.1463-1472, 2016. ,
Mutational landscape of MCPyVpositive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy, Oncotarget. 19 janv, vol.7, issue.3, pp.3403-3418, 2016. ,